Clinical trial · Observational
The Dynamic Process of VMB and Mucosal Immunity After FUS Treatment of CIN Patients With Fertility Requirement
The Dynamic Process of Vaginal Microbiota and Mucosal Immunity After Focused Ultrasound Treatment of Cervical Intraepithelial Neoplasia Patients With Fertility Requirement
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Cervical cancer is the fourth leading cause of cancer death in women worldwide, and cervical intraepithelial neoplasia (CIN) can progress to cervical cancer. Therefore, timely treatment of CIN is critical in preventing the occurrence of cervical cancer. With the implementation and promotion of the World Health Organization's 2030 Global Strategy for the Elimination of Cervical Cancer, an increasing number of women are detecting and treating CIN at an earlier stage. Common treatment methods include ablation treatment and excision treatment, but for women who are planning to have children, the risk of cervical insufficiency and pregnancy complications is greatly increased after excisional treatment, so ablation treatment seems to be a better choice.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cervical Intraepithelial Neoplasia | Cervical Intraepithelial Neoplasia | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Focused Ultrasound | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Treated women
- description
- HPV positive,pathology result indicate cervical intraepithelial neoplasia
- interventionNames
- Procedure: Focused Ultrasound
- label
- Healthy controls
- description
- HPV negative, normal cytology
Primary outcomes (5)
- measure
- Immunological indexes
- timeFrame
- We will get specimens in therapeutic day, after treatment 7-10 days,84-112days and 168-196 days respectively.
- description
- Immunological indexes(IFN-γ、IL-8、IL-10、IL-1β、SIgA) in cervical secretions will be measured by enzyme-linked immunosorbent assay (ELISA).
- measure
- Anti-microbial peptides
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: 1. patients aged 18-60 years old; 2. patients who had sexual life; 3. patients who had HPV infection; 4. patients who apply to ablation therapy 5. pathological report indicates CIN Exclusion Criteria: 1. pregnant or lactating women; 2. patients who had cervical treatment ; 3. patients who had genital tract infection ; 4. patients who had chronic diseases, such as allergic diseases ,autoimmune diseases and so on; 5. patients who received antibiotics or pessaries within 14 days of sampling.
References
Publications (0)
Data not yet available